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ISSBACKGROUND Cholesterol reduction with proprotein convertase subtilisin-kexin type 9 inhibitors reduces ischemic
events; however, the cost-effectiveness in statin-treated patients with recent acute coronary syndrome remains
uncertain.
OBJECTIVES This study sought to determine whether further cholesterol reduction with alirocumab would be
cost-effective in patients with a recent acute coronary syndrome on optimal statin therapy.
METHODS A cost-effectiveness model leveraging patient-level data from ODYSSEY OUTCOMES (Evaluation of
Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was developed to
estimate costs and outcomes over a lifetime horizon. Patients (n ¼ 18,924) had a recent acute coronary syndrome and
were on high-intensity or maximum-tolerated statin therapy, with a baseline low-density lipoprotein cholesterol (LDL-C)
level $70 mg/dl, non–high-density lipoprotein cholesterol $100 mg/dl, or apolipoprotein B $80 mg/l. Alirocumab
75 mg or placebo was administered subcutaneously every 2 weeks. Alirocumab was blindly titrated to 150 mg if LDL-C
remained $50 mg/dl or switched to placebo if 2 consecutive LDL-C levels were <15 mg/dl. Incremental cost per
quality-adjusted life-year (QALY) was determined with the addition of alirocumab versus placebo and, based on clinical
efficacy findings from the trial, was stratified by baseline LDL-C levels $100 mg/dl and <100 mg/dl.
RESULTS Across the overall population recruited to the ODYSSEY OUTCOMES trial, using an annual treatment cost of
US$5,850, the mean overall incremental cost-effectiveness ratio was US$92,200 per QALY (base case). The cost was
US$41,800 per QALY in patients with baseline LDL-C $100 mg/dl, whereas in those with LDL-C <100 mg/dl the cost per
QALY was US$299,400. Among patients with LDL-C $100 mg/dl, incremental cost-effectiveness ratios remained below
US$100,000 per QALY across a wide variety of sensitivity analyses.
CONCLUSIONS In patients with a recent acute coronary syndrome on optimal statin therapy, alirocumab
improves cardiovascular outcomes at costs considered intermediate value, with good value in patients with
baseline LDL-C $100 mg/dl but less economic value with LDL-C <100 mg/dl. (Evaluation of Cardiovascular
Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab [ODYSSEY OUTCOMES];
NCT01663402) (J Am Coll Cardiol 2020;75:2297–308) © 2020 The Authors. Published by Elsevier on behalf of
the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
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2298P otent reduction of low-density lipo-protein cholesterol (LDL-C) with pro-protein convertase subtilisinkexin
type 9 (PCSK9) inhibition improves cardiovas-
cular outcomes in high-risk patients (1–3).
Both the ODYSSEY OUTCOMES (Evaluation
of Cardiovascular Outcomes After an Acute
Coronary Syndrome During Treatment With
Alirocumab) (1) and FOURIER (Further Cardio-
vascular Outcomes Research with PCSK9 Inhi-
bition in Subjects with Elevated Risk) (3) trials
demonstrated a 15% relative risk reduction in
their respective primary endpoints, with
excellent safety and tolerability. Further-
more, in the ODYSSEY OUTCOMES trial, aliro-
cumab, compared with placebo, when added
to maximum-tolerated high-intensity statin
therapy was associated with a 15% lower all-
cause mortality (1,2).
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Nonfatal ischemic stroke 12,617
(11,35513,879)




Costs are expressed in 2018 U.S. dollars.
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2300of alirocumab, we undertook a trial-based cost-
effectiveness analysis using ODYSSEY OUTCOMES
patient-level data from the perspective of a U.S. pri-
vate payer.
METHODS
PATIENT POPULATION. The ODYSSEY OUTCOMES
trial design has been described (13). Briefly, the study
enrolled 18,924 patients 1 to 12 months post–acute
coronary syndrome (ACS) to evaluate the cardiovas-
cular efficacy and safety of adding alirocumab to
high-intensity or maximum-tolerated doses of sta-
tins. Patients were $40 years of age, had provided
written informed consent, been hospitalized with
ACS 1 to 12 months before randomization, and had
LDL-C levels $70 mg/dl (1.81 mmol/l) or non–high-
density lipoprotein cholesterol levels $100 mg/dl
(2.59 mmol/l) or apolipoprotein B levels $80 mg/dl
after $2 weeks of stable treatment with atorvastatin
40 to 80 mg daily, rosuvastatin 20 to 40 mg daily, or
the maximum tolerated dose of one of these statins.
After a pre-randomization run-in phase, patients
were randomly assigned (1:1) to blinded treatment
with alirocumab 75 mg or matching placebo, given by
subcutaneous injection every 2 weeks (see
Supplemental Methods). The patients were followed
for a median of 2.8 years (interquartile range: 2.3 to
3.4 years).
COST-EFFECTIVENESS MODEL STRUCTURE. Unlike
previous cost-effectiveness analyses, which used
Markov models (6–12), a trial-based model utilizing
patient-level data from ODYSSEY OUTCOMES was
developed to model costs and outcomes over a life-
time horizon. Supplemental Figure 1 presents the in-
puts and outputs of the ODYSSEY OUTCOMES–based
cost-effectiveness model. In the base-case analysis,
we used the intention-to-treat (ITT) population and
the impact on all-cause death observed from the trial.
Cardiovascular events of interest were fatal and
nonfatal myocardial infarction, nonfatal ischemic
stroke, unstable angina requiring hospitalization, and
coronary revascularization. Death was modeled
separately to avoid double counting events.
SURVIVAL AND EVENT RATE EXTRAPOLATION. To
extrapolate life expectancy using within-trial data,
the survival probability for patients in the placebo
arm was estimated using methods described by
Nelson et al. (14). With this approach, the cumulative
hazard function for all-cause death was estimated
from the trial using a left-truncated and right-
censored age–time scale based on a Cox proportional
hazards model. With this age-based model thatincorporates observed survival across ages of patients
represented in the trial, a fourth order of age poly-
nomial was fitted as reference survival probability.
Life expectancy for each patient in the placebo arm of
the trial was extrapolated with this model, account-
ing for the following baseline covariates: hyperten-
sion; anxiety; time from ACS event to randomization;
diabetes; and sex. To reduce prolonged survival
probabilities beyond age 80 years, a Gompertz model
(a 2-parameter exponential death acceleration func-
tion suggested by Nelson et al. [14]) was used wherein
the acceleration factor was consistent with that of
Nelson et al. (14), doubling the death rate every 8
years after 80 years of age. To estimate survival for
the alirocumab arm, the observed hazard ratio (HR)
for all-cause death between alirocumab and placebo
was applied to the extrapolated survival probability
for the placebo group.
Event rates per 100 patient-years, including total
events, for nonfatal myocardial infarction, nonfatal
ischemic stroke, unstable angina requiring hospitali-
zation, and coronary revascularization were estimated
based on the trial data for each treatment group. Rates
of nonfatal cardiovascular events observed in ODYS-
SEY OUTCOMES in each treatment arm throughout the
follow-up period were assumed to be constant over
the remaining life span of the patients.
HEALTH CARE RESOURCE USE AND COSTS. Fatal
and nonfatal cardiovascular events were mapped to
Medicare Diagnostic-Related Group codes by a panel
of nosologists. Mean Medicare Diagnostic-Related
Group payments from 2015 were used to calculate a
payment, weighted by each cardiovascular event type
(15), and updated to 2018 U.S. dollars using annual
rate increases published by the Centers for Medicare
and Medicaid Services (16). As Medicare reimburse-
ment rates are considerably lower than commercial
rates, we applied an inflation factor (1.88) to pa-
tients under 65 years of age (73.5%) to better reflect
payment for a commercial population. Mean inpa-
tient payments for cardiovascular death, nonfatal
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2301myocardial infarction, nonfatal ischemic stroke, un-
stable angina requiring hospitalization, and coronary
revascularization, are shown in Table 1.
The following algorithm was followed to ensure we
did not double count costs of cardiovascular events: if
a nonfatal myocardial infarction and an urgent
revascularization occurred on the same day, only the
cost of the revascularization was counted. Likewise, if
any cardiovascular event occurred on the same day as
a cardiovascular death, only cardiovascular death was
counted. If a fatal myocardial infarction and an ur-
gent revascularization occurred on the same day, the
model only accounted for cardiovascular death; if the
revascularization occurred on a different day, both
were counted. Otherwise all events were assigned
corresponding weighted-average payments to esti-
mate inpatient costs.
The annual cost of alirocumab was assumed to be
$5,850, reflective of the current list price not inclusive
of any potential rebates/discounts offered to payers.
An adherence rate was applied using the mean
number of injections per year observed in the trial
(21.8, 95% confidence interval [CI]: 21.7 to 22.0)
divided by the 26 injections expected per year. Use of
alirocumab was assumed to continue at this rate over
the remaining life span of the patient, without ac-
counting for future price reductions after loss of
patent protection.
UTILITY ANALYSIS. The EuroQol 5-dimensional
3-level (EQ-5D-3L) instrument (17), a generic
preference-based measure of health, was used to
assess each patient’s health status at baseline, every 2
to 4 months during the double-blind trial period, and
on trial termination. Responses to the 5 items
included in the EQ-5D-3L were converted to a utility
tariff score using the U.S. scoring algorithm reported
by Shaw et al. (18). A repeated-measures, mixed-
effects model (19) was used to regress utility values
on 4 major cardiovascular events (nonfatal myocar-
dial infarction, nonfatal ischemic stroke, unstable
angina requiring hospitalization, and coronary
revascularization) to estimate post-event decrements
in EQ-5D-3L utility values. Each of the 4 major car-
diovascular events was modeled using 2 indicator
variables: acute phase and long-term phase. The
acute phase indicated a cardiovascular event that
occurred within 90 days before the assessment of EQ-
5D-3L; the long-term phase indicated a cardiovascular
event that occurred more than 90 days before the
assessment. The EQ-5D-3L model also controlled for
age, sex, baseline EQ-5D-3L utility, cardiovascular
history, and diabetes at baseline. When modeling
health utilities over time, the mean age-adjusted
utility values were reduced by the acute-phasedisutilities estimated in the regression model for
nonfatal myocardial infarction, nonfatal ischemic
stroke, unstable angina requiring hospitalization, and
coronary revascularization, followed by chronic
phase disutilities for each event until death.
COST-EFFECTIVENESS ANALYSIS. Quality-adjusted
life-years (QALYs) and life-years gained were calcu-
lated for each year, accounting for the percentages of
patients to have died or to have had each type of car-
diovascular event in the current year, and the per-
centages with a history of cardiovascular events. Fatal
events were assumed to have occurred half-way
through the year. Acute-phase disutility weights
were applied to a quarter of the year in which cardio-
vascular events occurred, and chronic-phase disutility
weights were applied thereafter. After discounting,
QALYs across all years were summed for each
treatment group. The primary analysis was the
incremental cost-effectiveness ratio (ICER), defined as
the difference between mean discounted lifetime
costs divided by the difference in mean discounted
QALYs between the 2 treatment groups (i.e.,
alirocumab  placebo). Additionally, we estimated the
annual cost of alirocumab necessary for it to become
cost-effective at a commonly used willingness-to-pay
(WTP) threshold (i.e., $100,000 per QALY) (20). Costs
and QALYs were discounted at 3% per year (20).
COST-EFFECTIVENESS ACCEPTABILITY CURVES.
The variability of the estimation for ICERs in the base-
case analysis and sensitivity analyses were assessed
by nonparametric bootstrapping with 10,000 replica-
tions (21). In each bootstrap sample, patients were
randomly selected, with replacement within each
treatment group; the full sequence of analyses
described herein was executed. The percentages of
bootstrap replications falling below a range of WTP
thresholds were computed and plotted as cost-
effectiveness acceptability curves (CEACs). The 2.5
and 97.5 percentiles of the bootstrap distribution
provided the 95% confidence intervals for the ICERs.
SUBGROUP ANALYSIS. Post hoc analysis of ODYSSEY
OUTCOMES revealed a significant statistical interac-
tion between treatment with alirocumab and baseline
levels of LDL-C <100 mg/dl versus $100 mg/dl for
major adverse cardiovascular events and total
nonfatal cardiovascular events and a trend for all-
cause death (p ¼ 0.048, p ¼ 0.026, and p ¼ 0.057,
respectively) (Supplemental Methods). Considering
interest among health care payers in the United States
in identifying patients most likely to benefit from
higher-cost treatments, stratified results are pre-
sented for patients with baseline LDL-C
levels <100 mg/dl and $100 mg/dl.
TABLE 2 Model Input Parameters
Treatment Effect of Alirocumab
Event
HR (95% CI)
ITT Population (Base Case) Subgroup With LDL-C $100 mg/dl at Baseline Subgroup With LDL-C <100 mg/dl at Baseline
Cardiovascular death 0.88 (0.74 to 1.05) 0.68 (0.52 to 0.90) 1.03 (0.82 to 1.29)
All-cause death 0.85 (0.73 to 0.98) 0.70 (0.55 to 0.88) 0.95 (0.79 to 1.14)




All-cause death 1.24 (1.11 to 1.37) 1.46 (1.32 to 1.60)
Cardiovascular death 0.89 (0.78 to 1.00) 1.01 (0.89 to 1.13)
Nonfatal MI for disutility* 3.20 (2.91 to 3.50) 3.69 (3.39 to 4.01)
Nonfatal MI for cost* 2.70 (2.43 to 2.98) 3.12 (2.84 to 3.41)
Nonfatal ischemic stroke 0.44 (0.36 to 0.53) 0.62 (0.52 to 0.73)
Unstable angina requiring hospitalization 0.14 (0.09 to 0.19) 0.24 (0.18 to 0.30)
Ischemia-driven revascularization 3.19 (2.95 to 3.45) 3.70 (3.43 to 3.97)
Utility Analyses for the Base Case (ITT Population)
Analysis Time Frame Mean (95% CI)
Utilities
Baseline 0.893 (0.891 to 0.895)
Age 0.0005 (0.001 to 0.000)
Disutilities (acute or long term)
Nonfatal MI Acute† 0.028 (0.034 to 0.021)
Long term‡ 0.023 (0.027 to 0.018)
Nonfatal ischemic stroke Acute† 0.073 (0.090 to 0.056)
Long term‡ 0.069 (0.080 to 0.059)
Unstable angina requiring hospitalization Acute† 0.021 (0.045 to 0.003)
Long term‡ 0.001 (0.016 to 0.014)
Ischemia-driven revascularization Acute† 0.007 (0.014 to 0.001)
Long term‡ 0.002 (0.002 to 0.007)
*Event rate differs to avoid double-counting of events. †Event occurring within 90 days. ‡Event occurring after 90 days.
CI ¼ confidence interval; HR ¼ hazard ratio; ITT ¼ intention to treat; LDL-C ¼ low-density lipoprotein cholesterol; MI ¼ myocardial infarction.
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2302SENSITIVITY ANALYSES. Several sensitivity analyses
were performed to evaluate the impact on ICERs when
applying alternative assumptions to estimate ex-
pected survival. In 1 sensitivity analysis, the HR for the
effect of alirocumab on cardiovascular death (HR:
0.88; 95% CI: 0.74 to 1.05, for the ITT population) was
applied instead of the effect of alirocumab on all-cause
death (base case), whereby the effect of alirocumab
was applied to cardiovascular deaths, whereas no
treatment effect was applied to the noncardiovascular
death rate. The proportions of cardiovascular to all
deaths in the first 2 years were based on the placebo
group in ODYSSEY OUTCOMES (first year is 78% and
second year is 67%). The proportion of all deaths
attributed to cardiovascular causes at 3 years and
beyond (65%) was applied to all subsequent years.
Evidence for a 1-year delay in the beneficial treat-
ment effect of LDL-C lowering has been demonstrated
in randomized trials (3,22,23). Therefore, an additional
sensitivity analysis, which evaluated the impact ofalirocumab by applying separate HRs for mortality and
nonfatal cardiovascular events in the first year of
treatment and beyond the first year of follow-up in
ODYSSEY OUTCOMES, was undertaken.
One-way sensitivity analyses were performed us-
ing alternate values for model parameters to identify
key model drivers and the influence of parameter
uncertainty: cardiovascular event costs (10%); range
of utilities/disutilities (95% CIs); HRs for death and
nonfatal cardiovascular event rates in the placebo
arm (95% CIs).
All analyses were conducted in SAS (version 9.4,
SAS Software, Cary, North Carolina) and Excel
(version 2010, Microsoft, Redmond, Washington).
RESULTS
Demographic and clinical characteristics of the pop-
ulation have been described (1). The flow chart is
shown in Supplemental Figure 2. Briefly, the mean






















Life expectancy was extrapolated using within-trial data. The survival probability for patients in the placebo arm was estimated using the
cumulative hazard function for all-cause death, estimated from the trial based on a Cox proportional hazards model. To reduce prolonged
survival probabilities beyond 80 years of age, a Gompertz model (a 2-parameter exponential death acceleration function) was used. To
estimate survival for the alirocumab arm, the observed hazard ratio for all-cause death between alirocumab versus placebo was applied to
the extrapolated survival probability for the placebo group.
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2303age was 59  9 years, 75% (n ¼ 14,162) were men, and
79% (n ¼ 15,024) were white. Mean baseline LDL-C
was 92  31 mg/dl, with 89% receiving a high-
intensity statin at the time of randomization.
BASE-CASE ANALYSES. Surv iva l extrapolat ion
and card iovascula r event rates . Based on the
method of Nelson et al. (14), the average life expec-
tancy of the placebo group was 75.28 years (range
41.36 to 94.72 years). After applying the observed
average HR of 0.85 (95% CI: 0.73 to 0.98) (Table 2),
representing the impact of alirocumab on the rate of
all-cause death from the ITT population for the base-
case analysis, the extrapolated survival probabilities
over life-year are illustrated in Figure 1, giving a life
expectancy for alirocumab of 76.56 years. The
remaining years of survival (undiscounted) were
estimated at 17.32 (95% CI: 16.38 to 18.35) with alir-
ocumab and 16.06 (95% CI: 15.52 to 16.61) with pla-
cebo based on the area under the survival curves. The
discounted mean life-years were 13.07 (95% CI: 12.53
to 13.65) years in the alirocumab arm versus 12.33
(95% CI: 12.00 to 12.66) years in the placebo arm(Supplemental Table 1). Further validation details for
the model are provided in the Supplemental Methods
and Supplemental Figures 3 to 5. Table 2 displays the
rates for cardiovascular events per 100 patient-years
in the 2 treatment arms estimated from the trial for
the ITT population.
UTILITY ANALYSIS. Table 2 reports the results of the
mixed-effects regression analyses, showing the esti-
mated short-term and long-term impacts of total
nonfatal events on EQ-5D-3L health-utility weights in
the trial. After applying the disutility weights to the
extrapolated survival curves, the discounted mean
QALYs were 11.53 years in the alirocumab arm versus
10.87 years in the placebo arm, resulting in a differ-
ence of 0.66 gained QALYs in the alirocumab group in
the base-case analysis.
OVERALL AND STRATIFIED COST-EFFECTIVENESS.
In the base-case analysis, discounted lifetime costs per
patient in the alirocumab and placebo groups were
$97,400 and $36,100, respectively, representing an
increase of $61,300 with the addition of alirocumab to
background statin therapy. When accounting for a





























































































Parenthetical values are 95% CI. Costs are expressed in 2018 U.S. dollars and are rounded to nearest $100.
ICER ¼ incremental cost-effectiveness ratio; LY ¼ life-year; QALY ¼ quality-adjusted life-year; VBP ¼ value-based pricing; other abbreviations as in Table 2.
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23040.66 gain in QALYs with alirocumab versus placebo,
the ICER was estimated at $92,200 per QALY gained
(Table 3). At the $100,000 WTP threshold, the annual
value-based price for alirocumab was up to $6,319. The
CEAC revealed that 57.8% of replicates fell at or below
a $100,000 per QALY WTP threshold and 81.7% fell at
or below a $150,000 per QALY threshold (Central
Illustration). Event rates and utility values for pa-
tients with a baseline LDL-C $100 mg/dl and those
with a value <100 mg/dl are shown in Supplemental
Tables 2 and 3. If alirocumab treatment was restricted
to patients with a baseline LDL-C $100 mg/dl, the in-
cremental cost was $61,500 with an incremental QALY
of 1.47, leading to an ICER of $41,800 per QALY gained.
In patients with a baseline LDL-C <100 mg/dl, the in-
cremental cost was $60,500 with an incremental QALY
of 0.20, leading to an ICER of $299,400 (Supplemental
Table 4). The CEACs show that 97.1% of replicates
fell at or below the $100,000 per QALY WTP threshold
for the $100 mg/dl subgroup, and 12.4% for the
<100 mg/dl subgroup (Central Illustration).
SENSITIVITY ANALYSES. Input parameters for other
sensitivity analyses are reported in Supplemental
Table 5. When cardiovascular death was used in lieu
of all-cause death, the ICER increased to $173,800 per
QALY gained in the ITT population and $53,800 per
QALY gained in the $100 mg/dl subgroup. For mor-
tality and nonfatal cardiovascular events, when we
applied separate HRs in the first year of treatment and
beyond the first year of follow-up, the ICER decreased
to $66,600 per QALY in the ITT population
(Supplemental Table 6). The CEAC for the varying HRfrom the ITT population is shown in Supplemental
Figure 6 and for the cardiovascular HR in
Supplemental Figure 7. One-way sensitivity analyses,
performed using alternate values for model parame-
ters, showed that the main driver was the mortality
HR, whereas the utility, nonfatal cardiovascular event
rates, and cardiovascular event costs had limited
impact on the ICER (Supplemental Figure 8).
DISCUSSION
Using patient-level data from the ODYSSEY OUT-
COMES trial, we extrapolated observed survival to
determine the cost-effectiveness of alirocumab. In our
base-case analysis, the ICER was $92,200 per QALY,
which is considered as intermediate value as defined
in the American Heart Association/American College
of Cardiology guidelines. However, this figure masks
important differences in cost-effectiveness among
patients with a baseline LDL-C above or below
100 mg/dl. Among patients with a baseline LDL-C
$100 mg/dl, the ICER was more attractive, at $41,800
per QALY. This amount is below the $50,000 per QALY
benchmark suggested by American Heart Association/
American College of Cardiology to confer “high value”
for high-income countries (24). When additional ana-
lyses were conducted using the treatment effect for
cardiovascular death in lieu of all-cause death,
the results were consistent, with an ICER of $53,800
for patients with a baseline LDL-C $100 mg/dl. On the
other hand, in patients with a baseline LDL-C
<100 mg/dl, alirocumab use resulted in an ICER of
CENTRAL ILLUSTRATION Cost-Effectiveness Acceptability Curves (Intention-to-Treat Population)
for the Base Case (Overall Hazard Ratio) and Low-Density Lipoprotein Cholesterol$100 mg/dl











































Willingness to Pay per Quality-Adjusted Life-Year Gained ($)
Bhatt, D.L. et al. J Am Coll Cardiol. 2020;75(18):2297–308.
Cost-effectiveness acceptability curves (CEACs) summarize the impact of uncertainty on the result of an economic evaluation. The variability
of the estimation for incremental cost-effectiveness ratios in the base-case analysis was assessed by nonparametric bootstrapping with
10,000 replications. The y-axis is the probability of being cost-effective at any willingness-to-pay threshold (WTP) (x-axis). For example, for
all patients in the trial, at the $100,000 WTP threshold, alirocumab would be cost-effective at a price of $6,319 58% of the time. If the
threshold was $150,000, alirocumab would be cost-effective 82% of the time.
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2305$299,400 per QALY, which would be considered low
value (corresponding value-based prices at different
costs/QALYs are shown in Supplemental Table 7).
In the subgroup with LDL-C $100 mg/dl at base-
line, in which alirocumab appeared to demonstrate
good value, there is biological plausibility for its
increased value for money (1,2,25). Baseline risk in
these patients is generally higher than among pa-
tients with LDL-C <100 mg/dl. At the same time, a
higher LDL-C concentration at baseline is associated
with a larger absolute decrease in LDL-C under
treatment with alirocumab, yielding a greater effect
on risk reduction. Together, these findings make the
subgroup with baseline LDL-C $100 mg/dl clinically
relevant and easily identified in routine clinical
practice. Although we did not calculate cost effec-
tiveness in other subgroups, favorable value for
money with alirocumab treatment might also be ex-
pected in other patient categories defined by high
absolute risk of recurrent ischemic events and deathand large absolute benefit from treatment. Among
such subgroups identified in the ODYSSEY OUT-
COMES trial are those with diabetes, polyvascular
disease, prior coronary artery bypass surgery, or high
levels of lipoprotein(a) (26–29).
The current study is a trial-based analysis that uses
patient-level data obtained directly from the trial.
Our study differs from prior cost-effectiveness ana-
lyses of PCSK9 inhibition that utilized a Markov
transition-based model, which relies on aggregate
data from the trials (7,9–12). All model inputs for the
current study were obtained from ODYSSEY OUT-
COMES, whereas the prior analyses relied on data
inputs from outside the trial, such as background
event rates, treatment effect, and utility parameters.
Patient-level data provide further insights. For one,
we can account for patient characteristics associated
with mortality that would not be evident with trial-
level results. For instance, for a given mortality rate,
if younger patients more often died in the trial, there
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2306would be a greater reduction in life expectancy than if
older patients had died. There would be no way to
incorporate (or know) that from trial-level data.
Generally, using patient-level data facilitates sub-
group analyses because they inherently incorporate
relationships between patient characteristics and
rates of nonfatal events, mortality, and disutilities
that would not be accounted for in a trial-level anal-
ysis that may just change the HR for the treatment
effect in the corresponding subgroup. Given the
emphasis on cost-effectiveness in the 2018 U.S.
cholesterol-lowering guidelines (24), the present
approach may provide a useful tool for clinicians to
decide when to use a PCSK9 inhibitor after ACS.
Apart from the price of treatment, the 2 main
“drivers” of value are the background event rate and
survival benefit. In cardiovascular outcomes trials, the
latter ordinarily is the more important factor (30).
Some prior PCSK9 inhibitor cost-effectiveness ana-
lyses have either underestimated the background
cardiovascular event rate in the everyday clinical
practice or do not take into consideration the benefits
of averting death (7,12). With a very high-risk popu-
lation and longer duration of follow-up than previous
trials of PCSK9 inhibitors, fewer deaths were observed
with alirocumab than with placebo in the ODYSSEY
OUTCOMES trial. The trial therefore provides a rele-
vant dataset to project the effect of PCSK9 inhibition
after ACS on long-term survival and cost per QALY.
A limitation in previous models is the way death
was modeled. For example, 2 prior analyses (10,12)
used the cardiovascular disease policy model to
determine the cost-effectiveness of alirocumab or
evolocumab based on overall trial hazard ratios for
selected endpoints. Rather than giving “credit” for
averting death by applying trial-specific HRs for that
endpoint, Kazi et al. (12) stated that all-cause mor-
tality was mediated through a reduction in the risk of
death related to coronary heart disease and stroke.
For alirocumab, the assumed HR applied to account
for death was not the HR noted in the trial (0.85);
rather, an HR of 0.88 was used, which was the stated
HR for a major coronary heart disease event. In the
FOURIER trial, which tested PCSK9 inhibition with
evolocumab in patients with chronic atherosclerotic
cardiovascular disease, the HR (evolocumab/placebo)
for all-cause death was 1.05. In a cost-effectiveness
analysis of that trial, the HR for myocardial infarc-
tion was used to project a long-term effect on death
even though no mortality benefit was observed dur-
ing the trial (12). A time-varying HR of 0.80 for the
first year of treatment and 0.65 for the remaining
period of a patient’s life was assumed, resulting in a
value-based price of $4,200 per year for evolocumab.This analysis was recently updated, incorporating the
60% reduction in the annual U.S. list price from
$14,523 to $5,850 to the previous model. It also
focused on patients with very high-risk atheroscle-
rotic cardiovascular disease (defined by the new U.S.
guidelines) and high baseline cardiovascular event
rate assumptions, concluding that evolocumab is
cost-effective in very high-risk patients (11). Addi-
tionally, previous models did not consider all payer-
relevant endpoints, such as coronary revasculariza-
tion, which entails a high cost.
STUDY LIMITATIONS. Potential limitations of this
analysis include some of the assumptions in our
model.We did not use country-specific data, but rather
applied U.S. costs to the global population enrolled in
ODYSSEY OUTCOMES. The treatment effect of alir-
ocumab was applied to all-cause mortality, which in
the overall trial was nominally but not formally sta-
tistically significant according to pre-specified hierar-
chical testing. However, in the subgroup of patients
with LDL-C $100 mg/dl, the signal for mortality
reduction was amplified and was corroborated by a
significant reduction in cardiovascular mortality. The
median follow-up in the trial was 2.8 years, though, by
necessity, we extrapolated to (remaining) lifetime
survival and costs. We did not consider follow-up or
outpatient costs stemming from nonfatal cardiovas-
cular events (e.g., those associated with recurrent
hospitalization, rehabilitation, other medications, and
lost years of employment). Time from index ACS to the
beginning of randomization was incorporated as a co-
variate in the Nelson et al. model (14); based on our
model, we could not examine whether alirocumab
would be cost effective by delaying treatment. The
disutilities in our trial were of lower magnitude than
those applied in other publications (19), likely due to
the missing EQ-5D-3L assessments during the acute
phase of events. Our estimates include only the list
price of alirocumab and do not consider discounts
usually offered to payers. Finally, aside from our LDL-
C subgroups, we did not incorporate other important
subgroups, which could have higher baseline cardio-
vascular risk. In these respects, the present results
provide a conservative estimate of the cost-
effectiveness of alirocumab after ACS.
CONCLUSIONS
In a non-pre-specified subgroup analysis, we found
that at an annual list price of $5,850, alirocumab
represents good value for money in patients with ACS
and baseline LDL-C $100 mg/dl despite statin ther-
apy, though less value in patients with LDL-
C <100 mg/dl.
PERSPECTIVES
COMPETENCY IN SYSTEMS-BASED PRACTICE: Patient-
level health economic analysis suggests that to optimize value in
relation to cost PCSK9 inhibitor therapy should be directed to-
ward patients at highest risk, such as those with baseline LDL-C
levels $100 mg/dl.
TRANSLATIONAL OUTLOOK: Additional cost-effective stra-
tegies that reduce LDL-C and lower the risk of ischemic events
and death are needed for patients in whom statin therapy is not
sufficient.
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